Update breast cancer 2023 Part 1 – early stage breast cancer

Abstract: With abemaciclib (monarchE study) and olaparib (OlympiA study) gaining approval in the adjuvant treatment setting, a significant change in the standard of care for patients with early stage breast cancer has been established for some time now. Accordingly, some diverse developments are slowly being transferred from the metastatic to the adjuvant treatment setting. Recently, there have also been positive reports of the NATALEE study.


Other clinical studies are currently investigating substances that are already established in the metastatic setting. These include, for example, the DESTINY Breast05 study with trastuzumab deruxtecan and the SASCIA study with sacituzumab govitecan.


In this review paper, we summarize and place in context the latest developments over the past months

Show object

• Location: Deutsche Nationalbibliothek Frankfurt am Main
• Extent: Online-Ressource
• Language: Englisch
• Notes: Geburtshilfe und Frauenheilkunde. - 83, 06 (2023) , 653-663, ISSN: 1438-8804

Contributors, Places and Time

• Event: Veröffentlichung
• (where): Freiburg
• (who): Universität
• (when): 2023
• Creator: Hartkopf, Andreas ; Fasching, Peter Andreas ; Ţăran, Florin-Andrei ; Lüftner, Diana

Further information

• DOI: 10.1055/a-2074-0551
• URN: urn:nbn:de:bsz:25-freidok-2411967
• Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.